Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

RXRX Stock jumps after JPMorgan upgrade and trial data boost, fueling investor optimism in Recursion’s AI drug discovery ...

Recursion Pharmaceuticals (RXRX) stock rises after J.P. Morgan upgraded the biotech, citing a $1B+ sales potential for the ...

For decades, software developers have been slipping jokes into their work. One of the most enduring, clever, and geekily satisfying inside jokes has been hiding in plain sight: the recursive acronym.

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals Inc. (RXRX) reported its third-quarter 2025 earnings, revealing a mixed performance with an EPS of -$0.36, slightly surpassing the forecast of -$0.37. However, the company ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio ...